Biocon to launch anti-cholesterol drug in US market from FY13

12 Mar 2012 Evaluate

Biocon, Asia's premier biotechnology company, is all set to tap the US markets as the company is planning to sell its anti-cholesterol drug- atorvastatin- in the US from Financial Year (FY) 2013.

The US market for atorvastatin has recently opened up for generic companies. Further, the company plans to follow Watson and Ranbaxy, which have already launched their products in the markets and are currently under six months exclusivity phase.

The company has seen a significant growth in branded atorvastatin (Statix) as well as sales of active pharmaceutical ingredients (API). Similarly, Biocon is also planning to tap the European market, where it is currently selling atorvastatin with its partners. Biocon has major presence in emerging and unregulated markets with its branded atorvastatin (Statix).

Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.

Biocon Share Price

264.30 -1.15 (-0.43%)
16-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1536.95
Dr. Reddys Lab 6038.00
Cipla 1384.30
Zydus Lifesciences 937.80
Lupin 1613.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.